
Opinion|Videos|March 25, 2024
Widening the Therapeutic Window in The Management of Parkinson’s Disease
Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.
Advertisement
Episodes in this series
Timecodes:
1:20 Long-term challenges
2:58 Fluctuations in benefits
6:35 Therapeutic window
11:40 Amantadine ER for PD
14:33 Dyskinesia and treatment
18:18 Amantadine patients
23:14 Amantadine formulations
27:59 Early treatment & future
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA PDUFA Watch: Neurology Decisions to Track Through Late September
2
FDA Clears VoxNeuro's EEG-Based Cognitive Assessment Software
3
FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1
4
Favorable Phase 1 Data for Orexin-2 Agonist BP-205, Broader Pipeline Progress Headline Harmony's Q2 Update
5















